Timothy Coughlin Biography and Net Worth

Director of Travere Therapeutics

Timothy Coughlin, CPA, has served as a director of Travere Therapeutics since March 2015. Mr. Coughlin is the former chief financial officer of Neurocrine Biosciences, Inc., a biopharmaceutical company that received FDA approval for INGREZZA (valbenazine) and ORILISSA (elagolix), both of which were discovered and developed during his tenure at Neurocrine from 2002 to 2018. Mr. Coughlin currently serves on the board of directors of ADC Therapeutics SA, and as the chair of the board of directors of aTyr Pharma, Inc., both biotechnology companies, and previously served on the board of directors of Peloton Therapeutics, Inc. prior to its sale to Merck in 2019 and on the board of Fate Therapeutics from 2013 to 2025. Prior to joining Neurocrine, he was with Catholic Health Initiatives, a nationwide integrated healthcare delivery system, where he served as vice president, Financial Services. Earlier in his career Mr. Coughlin served as a senior manager in the health sciences practice of Ernst & Young LLP and its predecessors. Mr. Coughlin holds a master’s degree in international business from San Diego State University and a bachelor’s degree in accounting from Temple University. Mr. Coughlin is a certified public accountant in both California and Pennsylvania.

What is Timothy Coughlin's net worth?: The estimated net worth of Timothy Coughlin is at least $1.94 million as of October 31st, 2025. Mr. Coughlin owns 55,500 shares of Travere Therapeutics stock worth more than $1,942,500 as of December 8th. This net worth approximation does not reflect any other assets that Mr. Coughlin may own. Learn More about Timothy Coughlin's net worth.
How do I contact Timothy Coughlin?: The corporate mailing address for Mr. Coughlin and other Travere Therapeutics executives is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. Travere Therapeutics can also be reached via phone at (888) 969-7879 and via email at [email protected]. Learn More on Timothy Coughlin's contact information.
Has Timothy Coughlin been buying or selling shares of Travere Therapeutics?: During the last quarter, Timothy Coughlin has sold $630,540.00 in Travere Therapeutics stock. Most recently, Timothy Coughlin sold 18,000 shares of the business's stock in a transaction on Friday, October 31st. The shares were sold at an average price of $35.03, for a transaction totalling $630,540.00. Following the completion of the sale, the director now directly owns 55,500 shares of the company's stock, valued at $1,944,165. Learn More on Timothy Coughlin's trading history.
Who are Travere Therapeutics' active insiders?: Travere Therapeutics' insider roster includes Steve Aselage (Director), Roy Baynes (Director), Sandra Calvin (CAO), Laura Clague (CFO), Christopher Cline (Chief Financial Officer), Timothy Coughlin (Director), Eric Dube (CEO), Peter Heerma (Insider), Jula Inrig (Insider), Gary Lyons (Director), Jeffrey Meckler (Director), Elizabeth Reed (SVP), Noah Rosenberg (Insider), and William Rote (SVP). Learn More on Travere Therapeutics' active insiders.
Are insiders buying or selling shares of Travere Therapeutics?: During the last year, insiders at the sold shares 34 times. They sold a total of 473,618 shares worth more than $12,860,345.10. The most recent insider tranaction occured on December, 1st when CFO Christopher R Cline sold 20,000 shares worth more than $700,200.00. Insiders at Travere Therapeutics own 4.1% of the company. Learn More about insider trades at Travere Therapeutics.
Information on this page was last updated on 12/1/2025.

Timothy Coughlin Insider Trading History at Travere Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/31/2025	Sell	18,000	$35.03	$630,540.00	55,500

Timothy Coughlin Buying and Selling Activity at Travere Therapeutics

Travere Therapeutics Company Overview

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $35.00

$34.52

$35.59

50 Day Range

MA: $31.05

$23.90

$36.47

2 Week Range

Now: $35.00

$12.91

$37.50

Volume

1,573,784 shs

Average Volume

1,443,075 shs

Market Capitalization

$3.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89